Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.30 |
| ▸ | MTOR | P42345 | 2/20 | 0.30 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29720448 | 0.89 | PDE10A (0.35) | HIF1ANPSR1SMN1; SMN2 | |
| SCHEMBL24127737 | 0.89 | PDE10A (0.35) | HIF1ANPSR1SMN1; SMN2 | |
| SCHEMBL26038290 | 0.89 | HIF1A (0.37) | HIF1ASMONPSR1CFTRMETAP1 | |
| SCHEMBL29720410 | 0.88 | HIF1A (0.33) | HIF1ASMONPSR1CFTRMETAP1 | |
| SCHEMBL24127729 | 0.88 | HIF1A (0.33) | HIF1ASMONPSR1CFTRMETAP1 | |
| SCHEMBL26038934 | 0.88 | HPGD (0.31) | — | |
| SCHEMBL26038293 | 0.86 | POLB (0.38) | HIF1ACFTRMETAP1KMT2A | |
| SCHEMBL26038982 | 0.86 | KDM4E (0.35) | NPSR1CFTRMETAP1KMT2ASMN1; SMN2 | |
| SCHEMBL29720528 | 0.82 | KDM4E (0.34) | NPSR1CFTRMETAP1KMT2ASMN1; SMN2 | |
| SCHEMBL24128070 | 0.82 | KDM4E (0.34) | NPSR1CFTRMETAP1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, G3BP1, NRAS | HIF1A 2256/4885SMO 520/4885NPSR1 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.